Advanced pharmaceutical bulletin最新文献_第8页

Transdermal Drug Delivery Systems: A Focused Review of the Physical Methods of Permeation Enhancement 透皮给药系统:渗透增强物理方法的重点综述

Advanced pharmaceutical bulletin Pub Date : 2023-10-14 DOI: 10.34172/apb.2024.018

Rifath Sheikh Vaseem, Alison D’cruz, Srishti Shetty, Hafsa -, Aditya Vardhan, Shreya Shenoy R, Shirleen Miriam Marques, Lalit Kumar, Ruchi Verma

{"title":"Transdermal Drug Delivery Systems: A Focused Review of the Physical Methods of Permeation Enhancement","authors":"Rifath Sheikh Vaseem, Alison D’cruz, Srishti Shetty, Hafsa -, Aditya Vardhan, Shreya Shenoy R, Shirleen Miriam Marques, Lalit Kumar, Ruchi Verma","doi":"10.34172/apb.2024.018","DOIUrl":"https://doi.org/10.34172/apb.2024.018","url":null,"abstract":"The skin is the body's largest organ and serves as a site of administration for various medications. Transdermal drug delivery systems have several advantages over traditional delivery systems. It has both local and systemic therapeutic properties. Controlled plasma drug levels, reduced dosing frequency, and avoidance of hepatic first-pass metabolism are just a few of these systems' advantages. To achieve maximum efficacy, it is critical to understand the kinetics, physiochemical properties of the drug moiety, and drug transport route. This manuscript focused on the principles of various physical means to facilitate transdermal drug delivery. Some examples are iontophoresis, electrophoresis, photomechanical waves, ultrasound, needleless injections, and microneedles. Mechanical, chemical, magnetic, and electrical energy are all used in physical methods. A major advantage of physical methods is their capability to abbreviate pain, which can be used for effective disease management. Further investigation should be carried out at the clinical level to understand these methods for effective drug delivery.","PeriodicalId":7256,"journal":{"name":"Advanced pharmaceutical bulletin","volume":"2011 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135803828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A comprehensive review on Novel Lipid- Based nano drug delivery 新型脂质纳米给药技术综述

Advanced pharmaceutical bulletin Pub Date : 2023-10-14 DOI: 10.34172/apb.2024.012

Sonam Suresh Godase, Nilesh Shrikant Kulkarni, Shashikant Nivrutti Dhole

引用次数: 0

AMPK signaling pathway as a potential therapeutic target for Parkinson's disease AMPK信号通路作为帕金森病的潜在治疗靶点

Advanced pharmaceutical bulletin Pub Date : 2023-10-14 DOI: 10.34172/apb.2024.013

Seyed Zanyar Athari, Fereshteh Farajdokht, Rana Keyhanmanesh, Gisou Mohaddes

引用次数: 0

Green formulation of spironolactone loaded chitosan coated nano lipid carrier for treatment of acne vulgaris: a randomized double-blind clinical trial 绿色配方载螺内酯壳聚糖包被纳米脂质载体治疗寻常性痤疮:随机双盲临床试验

Advanced pharmaceutical bulletin Pub Date : 2023-09-23 DOI: 10.34172/apb.2024.011

Majid Saeedi, Katayoun Morteza-Semnani, Jafar Akbari, Zohreh Hajheydari, Amin Goodarzi, Seyyed Sohrab Rostamkalaei, Seyyed Mohammad Hassan Hashemi, Seyyed Mobin Rahimnia

{"title":"Green formulation of spironolactone loaded chitosan coated nano lipid carrier for treatment of acne vulgaris: a randomized double-blind clinical trial","authors":"Majid Saeedi, Katayoun Morteza-Semnani, Jafar Akbari, Zohreh Hajheydari, Amin Goodarzi, Seyyed Sohrab Rostamkalaei, Seyyed Mohammad Hassan Hashemi, Seyyed Mobin Rahimnia","doi":"10.34172/apb.2024.011","DOIUrl":"https://doi.org/10.34172/apb.2024.011","url":null,"abstract":"Purpose: Spironolactone (SPN), which is classified as an anti-androgen, has demonstrated efficacy in treating acne. This study aimed to utilize ultrasonication to create a chitosan-coated nano lipid carrier (NLC) for enhancing the delivery of SPN to the skin and treating acne. Methods: Various Hydrophilic-Lipophilic Balance (HLB) values were investigated to optimize the SPN-NLCs. Photon correlation spectroscopy, attenuated total reflectance-Fourier transform infrared spectroscopy (ATR-FTIR), transmission electron microscopy (TEM), and differential scanning calorimetry (DSC) were employed to characterize the solid state of SPN in nanoparticle form. Additionally, the optimized formulation was used in a double-blind, randomized clinical trial. Results: Reducing the HLB of the surfactant mixtures resulted in a reduction in the size of SPN-NLCs. The formula with the smallest particle diameter (238.4±0.74 nm) and the lowest HLB value (9.65) exhibited the highest encapsulation efficiency of 79.88 ± 1.807%. Coating the optimized SPN-NLC with chitosan increased the diameter, PDI, zeta potential, and encapsulation efficiency. In vitro skin absorption studies demonstrated sustained release profiles for chitosan-coated SPN-NLC. In the double-blind trial, a gel containing chitosan-coated SPN-NLC effectively treated mild to moderate acne vulgaris, leading to improved healing and reduced lesion count after 8 weeks of therapy compared to the placebo. It successfully addressed both non-inflammatory and inflammatory lesions without adverse effects on the skin. Conclusion: The findings indicate that chitosan-coated SPN-NLCs have the potential as nanoparticles for targeted SPN delivery to the skin, offering novel options for the treatment of acne vulgaris.","PeriodicalId":7256,"journal":{"name":"Advanced pharmaceutical bulletin","volume":"9 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136010485","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Revolutionizing hyperlipidemia treatment: Nanoencapsulated CoQ10 and selenium combat simvastatin-induced myopathy and insulin resistance in rats 革命性的高脂血症治疗:纳米胶囊化辅酶q10和硒对抗辛伐他汀诱导的大鼠肌病和胰岛素抵抗

Advanced pharmaceutical bulletin Pub Date : 2023-09-23 DOI: 10.34172/apb.2024.010

Hager A Zalam, Ezz ElDeen Saeed El Denshary, Rania Mohsen, Islam Khlail, Mahmoud Khattab, Mohamed Hamzawy

{"title":"Revolutionizing hyperlipidemia treatment: Nanoencapsulated CoQ10 and selenium combat simvastatin-induced myopathy and insulin resistance in rats","authors":"Hager A Zalam, Ezz ElDeen Saeed El Denshary, Rania Mohsen, Islam Khlail, Mahmoud Khattab, Mohamed Hamzawy","doi":"10.34172/apb.2024.010","DOIUrl":"https://doi.org/10.34172/apb.2024.010","url":null,"abstract":"Purpose: The objective of this study was to develop a nanoencapsulated platform for Coenzyme Q10 (coQNPs) or selenium (SeNPs) and explore their potential therapeutic benefits in treating hyperlipidemia and combating simvastatin-induced myopathy and adverse reactions in hyperlipidemic rats. Methods: The physical and chemical properties of the solid nanoparticles (SLNPs), coQNPs, and SeNPs were characterized, including zeta potential studies. Male Wistar albino rats were treated with various interventions for 112 days, including a nano-vehicle only, high-fat diet (HFD), HFD with simvastatin alone, or with coQNPs or/ and SeNPs for the last 30 days. Results: The coQNPs and SeNPs exhibited uniform spherical shapes with high encapsulation efficiency (EE% 91.20 ±2.14 and 94.89 ±1.54, respectively). The results demonstrated that coQNPs and SeNPs effectively reduced hyperlipidemia, insulin resistance, simvastatin-induced myopathy, and hepatotoxicity. However, combining simvastatin with coQNPs and SeNPs resulted in severe liver and muscle damage. Treatment with simvastatin and SeNPs or simvastatin and coQNPs alone showed significant improvements compared to simvastatin treatment alone. Conclusion: These findings suggest that the CoQNPs or SeNPs platforms offer advanced relief for hyperlipidemia and insulin resistance while limiting adverse effects such as myopathy and hepatotoxicity.","PeriodicalId":7256,"journal":{"name":"Advanced pharmaceutical bulletin","volume":"35 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136010357","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Does exercise affect cancer via reverse cholesterol transport process? A hypothesis which needs to be clarified by researchers 运动是否通过逆向胆固醇运输过程影响癌症?这是一个需要研究人员澄清的假设

Advanced pharmaceutical bulletin Pub Date : 2023-08-27 DOI: 10.34172/apb.2024.008

Saleh Rahmati, Hasan Taherkhani, Aliasghar Zarezadehmehrizi, Lida Moradi

引用次数: 0

Recent progress in the oral delivery of therapeutic peptides and proteins: Overview of pharmaceutical strategies to overcome absorption hurdles 治疗性多肽和蛋白质口服递送的最新进展:克服吸收障碍的药物策略概述

Advanced pharmaceutical bulletin Pub Date : 2023-08-26 DOI: 10.34172/apb.2024.009

Sonal Mehrotra, Pavan Kalyan BG, Pawan G Nayak, Alex Joseph, Jyothsna Manikkath

{"title":"Recent progress in the oral delivery of therapeutic peptides and proteins: Overview of pharmaceutical strategies to overcome absorption hurdles","authors":"Sonal Mehrotra, Pavan Kalyan BG, Pawan G Nayak, Alex Joseph, Jyothsna Manikkath","doi":"10.34172/apb.2024.009","DOIUrl":"https://doi.org/10.34172/apb.2024.009","url":null,"abstract":"Objective: This review aims to critically examine and summarize the innovations and mechanisms involved in oral delivery of peptide and protein drugs. Significance: Proteins and peptides have secured a place as excellent therapeutic moieties on account of their high selectivity and efficacy. However due to oral absorption limitations, current formulations are mostly delivered parenterally. Oral delivery of peptides and proteins can be considered the need of the hour due to the immense benefits of this route. Methods: Comprehensive literature search was undertaken, spanning the early development to the current state of the art, using online search tools (PubMed, Google Scholar, ScienceDirect and Scopus). Results: Research in oral delivery of proteins and peptides has a long and rich history and the development of biologics has encouraged additional research effort in recent decades. Enzyme hydrolysis and inadequate permeation into intestinal mucosa are the major causes that result in limited oral absorption of biologics. Pharmaceutical and technological strategies including use of absorption enhancers, enzyme inhibition, chemical modification (PEGlyation, pro-drug approach, peptidomimetics, glycosylation), particulate delivery (polymeric nanoparticles, liposomes, micelles, microspheres), site-specific delivery in the GIT, membrane transporters, novel approaches (self-nanoemulsifying drug delivery systems, Eligen technology, peptelligence, self-assembling bubble carrier approach, luminal unfolding microneedle injector, microneedles) and lymphatic targeting, are discussed. Limitations of these strategies and future innovations for improving oral bioavailability of protein and peptide drugs are also discussed. Conclusion: This review underlines the application of oral route for peptide and protein delivery, which can direct the formulation scientist for better exploitation of this route.","PeriodicalId":7256,"journal":{"name":"Advanced pharmaceutical bulletin","volume":"55 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135237213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

MicroRNAs as Targets for Cancer Diagnosis: Interests and Limitations. 作为癌症诊断靶点的微 RNA：兴趣与局限。

IF 3.1

Advanced pharmaceutical bulletin Pub Date : 2023-07-01 Epub Date: 2022-07-02 DOI: 10.34172/apb.2023.047

Behrouz Shademan, Vahidreza Karamad, Alireza Nourazarian, Sepideh Masjedi, Alireza Isazadeh, Fatma Sogutlu, Cigir Biray Avcı

{"title":"MicroRNAs as Targets for Cancer Diagnosis: Interests and Limitations.","authors":"Behrouz Shademan, Vahidreza Karamad, Alireza Nourazarian, Sepideh Masjedi, Alireza Isazadeh, Fatma Sogutlu, Cigir Biray Avcı","doi":"10.34172/apb.2023.047","DOIUrl":"10.34172/apb.2023.047","url":null,"abstract":"MicroRNAs are small RNAs with ability to attach to the large number of RNA that regulate gene expression on post-transcriptional level via inhibition or degradation of specific mRNAs. MiRNAs in cells are the primary regulators of functions such as cell growth, differentiation, and apoptosis and considerably influence cell function. The expression levels of microRNAs change in human diseases, including cancer. These changes highlight their essential role in cancer pathogenesis. Ubiquitous irregular expression profiles of miRNAs have been detected in various human cancers using genome-wide identification techniques, which are emerging as novel diagnostic and prognostic cancer biomarkers of high specificity and sensitivity. The measurable miRNAs with enhanced stability in blood, tissues, and other body fluids provide a comprehensive source of miRNA-dependent biomarkers for human cancers. The leading role of miRNAs as potential biomarkers in human cancers is discussed in this article. In addition, the interests and difficulties of miRNAs as biomarkers have been explored.","PeriodicalId":7256,"journal":{"name":"Advanced pharmaceutical bulletin","volume":"13 3","pages":"435-445"},"PeriodicalIF":3.1,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10460809/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10118316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Fluvoxamine Mediates Specific, Early, and Delayed SARS-CoV-2 Protection through Antioxidant and Cytoprotective Pathways via Sigma-1 Receptor Agonism. 氟伏沙明通过Sigma-1受体激动作用通过抗氧化和细胞保护途径介导特异性、早期和延迟的SARS-CoV-2保护。

IF 3.6

Advanced pharmaceutical bulletin Pub Date : 2023-07-01 DOI: 10.34172/apb.2023.045

Konstantinos Papadopoulos, Alexandra Papadopoulou, Tar Choon Aw

引用次数: 0

Drug Delivery of Solid Lipid Nanoparticles (SLNs) and Nanostructured Lipid Carriers (NLCs) to Target Brain Tumors. 固体脂质纳米颗粒(SLNs)和纳米结构脂质载体(NLCs)靶向脑肿瘤的药物递送。

IF 3.6

Advanced pharmaceutical bulletin Pub Date : 2023-07-01 DOI: 10.34172/apb.2023.062

Soheil Mehrdadi

{"title":"Drug Delivery of Solid Lipid Nanoparticles (SLNs) and Nanostructured Lipid Carriers (NLCs) to Target Brain Tumors.","authors":"Soheil Mehrdadi","doi":"10.34172/apb.2023.062","DOIUrl":"https://doi.org/10.34172/apb.2023.062","url":null,"abstract":"Brain, predisposed to local and metastasized tumors, has always been the focus of oncological studies. Glioblastoma multiforme (GBM), the most common invasive primary tumor of the brain, is responsible for 4% of all cancer-related deaths worldwide. Despite novel technologies, the average survival rate is 2 years. Physiological barriers such as blood-brain barrier (BBB) prevent drug molecules penetration into brain. Most of the pharmaceuticals present in the market cannot infiltrate BBB to have their maximum efficacy and this in turn imposes a major challenge. This mini review discusses GBM and physiological and biological barriers for anticancer drug delivery, challenges for drug delivery across BBB, drug delivery strategies focusing on SLNs and NLCs and their medical applications in on-going clinical trials. Numerous nanomedicines with various characteristics have been introduced in the last decades to overcome the delivery challenge. Solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) were introduced as oral drug delivery nanomedicines which can be encapsulated by both hydrophilic and lipophilic pharmaceutical compounds. Their biocompatibility, biodegradability, lower toxicity and side effects, enhanced bioavailability, solubility and permeability, prolonged half-life and stability and finally tissue-targeted drug delivery makes them unique among all.","PeriodicalId":7256,"journal":{"name":"Advanced pharmaceutical bulletin","volume":"13 3","pages":"512-520"},"PeriodicalIF":3.6,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10460802/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10121084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1